Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study

Wittkop, Linda; Günthard, Huldrych F.; Wolf, Frank de; Dunn, David; Cozzi‐Lepri, Alessandro; Luca, Andrea De; Kücherer, Claudia; Obel, Niels; Wyl, Viktor von; Masquelier, Bernard; Stephan, Christoph; Torti, Carlo; Antinori, Andrea; García, Féderico; Judd, Ali; Porter, Kholoud; Thiébaut, Rodolphe; Castro, Hannah; Sighem, A.I. van; Colin, Céline; Kjær, Jesper; Lundgren, Jens D.; Paredes, Roger; Pozniak, Anton; Clotet, Bonaventura; Phillips, Andrew; Pillay, Deenan; Chêne, Geneviève

doi:10.1016/s1473-3099(11)70032-9

Cited by 353 publications

(307 citation statements)

References 28 publications

Supporting

Mentioning

283

Contrasting

Unclassified

Order By: Relevance

“…If available, the antiretroviral history of the mother or other source case should also be documented. In view of the possibility of transmitted drug resistance 18, 19 and unreported prior ART exposure, HIV genotypic resistance testing is recommended at baseline (including reverse transcriptase, protease and integrase resistance testing when available). If available, the results of resistance testing of the source case, as close as possible to the time of transmission, should also be documented.…”

Section: Diagnosis Baseline Investigations and Pretreatment Monitoringmentioning

confidence: 99%

See 1 more Smart Citation

Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV‐1 infection 2015: optimizing health in preparation for adult life

et al. 2015

View full text Add to dashboard Cite

The 2015 Paediatric European Network for Treatment of AIDS (PENTA) guidelines provide practical recommendations on the management of HIV‐1 infection in children in Europe and are an update to those published in 2009. Aims of treatment have progressed significantly over the last decade, moving far beyond limitation of short‐term morbidity and mortality to optimizing health status for adult life and minimizing the impact of chronic HIV infection on immune system development and health in general. Additionally, there is a greater need for increased awareness and minimization of long‐term drug toxicity. The main updates to the previous guidelines include: an increase in the number of indications for antiretroviral therapy (ART) at all ages (higher CD4 thresholds for consideration of ART initiation and additional clinical indications), revised guidance on first‐ and second‐line ART recommendations, including more recently available drug classes, expanded guidance on management of coinfections (including tuberculosis, hepatitis B and hepatitis C) and additional emphasis on the needs of adolescents as they approach transition to adult services. There is a new section on the current ART ‘pipeline’ of drug development, a comprehensive summary table of currently recommended ART with dosing recommendations. Differences between PENTA and current US and World Health Organization guidelines are highlighted and explained.

show abstract

Section: Diagnosis Baseline Investigations and Pretreatment Monitoringmentioning

confidence: 99%

“…Although transmitted viral resistance remains rare in children, it may lead to suboptimal response to the first‐line treatment 19. Therefore, pretreatment resistance genotyping should be performed.…”

Section: Which Art Regimen To Start As First‐line Therapymentioning

confidence: 99%

Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV‐1 infection 2015: optimizing health in preparation for adult life

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Related to malaria, foci of artemisinin resistance have been identified in multiple countries in Southeast Asia; further spread or emergence in other regions of this resistance could jeopardize important gains in malaria control made since 2000 [14]. Finally, increasing levels of transmitted anti-HIV drug resistance have been detected among patients starting antiretroviral treatment in low-and middle-income countries; available data suggest that 10%-17% of patients without prior history of ART in high income countries are infected with virus resistant to at least one antiretroviral drug [15][16][17][18].…”

Section: Current Global Burden Of Amrmentioning

confidence: 99%

The global response to the threat of antimicrobial resistance and the important role of vaccines

Utt

Wells

2016

PPL

View full text Add to dashboard Cite

“…Knowledge of ART resistance is described as a predictor of immunologic, virologic, and clinical outcomes of therapy [10]. Consequently, the identification of HIVDR in treatment-naive patients is critical to maximize the detection of transmitted drug resistance, guide the selection of treatment regimen to suppress HIV-1 replication, and ultimately prevent resistance-associated virologic failure [9,11,12]. The prevalence of HIVDR among ART-naive people in the United States and Europe has been estimated to be 10%-15% [11,13].…”

Section: Introductionmentioning

confidence: 99%

“…Consequently, the identification of HIVDR in treatment-naive patients is critical to maximize the detection of transmitted drug resistance, guide the selection of treatment regimen to suppress HIV-1 replication, and ultimately prevent resistance-associated virologic failure [9,11,12]. The prevalence of HIVDR among ART-naive people in the United States and Europe has been estimated to be 10%-15% [11,13]. In sub-Saharan Africa, HIVDR was reported to be less than 5%, with growing evidence of increasing levels of resistance [14,15,16].…”

Section: Introductionmentioning

confidence: 99%

Screening for antiretroviral drug resistance among treatment-naive human immunodeficiency virus type 1-infected individuals in Lebanon

Mokhbat

Melhem

El‐Khatib

et al. 2014

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: Antiretroviral therapy (ART) has been successful at decreasing the morbidity and mortality associated with human immunodeficiency virus type 1 (HIV-1) infection. HIV-1 drug resistance (HIVDR) among ART-naive patients has been documented to compromise the success of initial therapy. This study was conducted to determine the prevalence of HIVDR mutations among newly diagnosed drug-naive HIV-infected individuals in Lebanon. Methodology: Plasma samples from 37 newly diagnosed participants at various stages of HIV-1 infection were used to determine HIV-1 RNA viral load, isolate viral RNA, and amplify DNA by RT-PCR. Purified PCR products were used to perform genotypic resistance tests. Results: The prevalence of resistance mutations to nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRT), and protease inhibitors (PI) were 5.4%, 10.8%, and 8%, respectively. The major mutations detected in the study participants conferred resistance to NRTIs and NNRTIs recommended for HIV-1 treatment. No significant relationship between HIV-1 viral load of participants and the mode of HIV-1 transmission or between the occurrence of HIVDR and the mode of transmission was found. Conclusions: To our knowledge, this is the first study on HIVDR mutations among newly diagnosed HIV-infected persons in Lebanon. The overall prevalence of HIVDR mutations detected in our study was 16%. Our results are important for evaluating the utility of the standard first-line regimens in use, determining the feasibility of HIVDR testing before the initiation of ART, as well as minimizing the emergence and transmission of HIVDR.

show abstract

Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study

Cited by 353 publications

References 28 publications

Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV‐1 infection 2015: optimizing health in preparation for adult life

Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV‐1 infection 2015: optimizing health in preparation for adult life

The global response to the threat of antimicrobial resistance and the important role of vaccines

Screening for antiretroviral drug resistance among treatment-naive human immunodeficiency virus type 1-infected individuals in Lebanon

Contact Info

Product

Resources

About